Multi-targets or single-molecule peptides with combined agonistic effects of GIPR, GLP-1R and GCGR have been widely explored
Large meals become uncomfortable or impossible as gastric emptying slows and fullness signals intensify
On MyCrohnsAndColitisTeam, members come together to ask questions, give advice, and share their stories with others who understand life with Crohns and colitis
In trials of the combination of GLP-1 and GIP agonists, patients lost an average of 25% of their initial body weight at the highest dose. GLP-1 medications, which are available by prescription only and administered by weekly injection, are approved for people with a body mass index above 30, or above 27 with a comorbidity, such as type 2 diabetes, prediabetes, high blood pressure or sleep apnea
This can help you feel more stable and improve your health over time
A phase II trial focusing on individuals with overweight or obesity, coupled with hypertension or dyslipidemia but without T2D, found that cagrilintide (2.4 mg) alongside diet and exercise, led to a 10% body weight reduction compared to 3% with placebo over 26 weeks [99]